Rodabe N. Amaria, M.D.

Peer-Reviewed Articles

1. Novis E, Rautalin M, Amaria RN, Ascierto PA, Blank CU, Faries MB, Grunhagen DJ, Gyorki DE, Hayes AJ, Kuijpers AMJ, Long GV, Mammen JMV, Menzies AM, Ross MI, Rutkowski P, Tawbi HA, Tetzlaff MT, Zager JS, Wargo JA, Hieken TJ, van Akkooi ACJ. ASO Visual Abstract: International Survey on Evidence for Index Lymph Node Surgery Following Neoadjuvant Systemic Therapy for Stage III Melanoma. Ann Surg Oncol, 2026. e-Pub 2026. PMID: 41575642.
2. Robert M, Saha S, Dizman N, Rohlfs M, Sirmans E, Simon J, Amaria RN, Glitza Oliva IC, Tawbi HA, Davies MA, Ikeguchi A, Basen-Engquist K, Schadler K, Roth ME, Song W, Zhang X, Ajami NJ, Cohen L, Wargo JA, Peterson CB, McQuade JL, Daniel CR. Investigating Chronic Toxicity, Diet, Patient-Reported Outcomes and the Microbiome in Immunotherapy-Treated Metastatic Melanoma Survivors: A New Frontier. Nutrients 18(1), 2025. e-Pub 2025. PMID: 41515159.
3. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov 15(12):2574, 2025. e-Pub 2025. PMID: 41327972.
4. Hasanov M, Kiany S, Forget MA, Bassett R, Davies MA, Diab A, Gershenwald JE, Glitza IC, Lee JE, Lucci A, McQuade JL, Patel SP, Ross MI, Tawbi HA, Wargo JA, Wong MK, Bernatchez C, Hwu P, Haymaker C, Amaria RN. Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma. Oncoimmunology 14(1):2546402, 2025. e-Pub 2025. PMID: 40815607.
5. Novis E, Rautalin M, Amaria RN, Ascierto PA, Blank CU, Faries MB, Grunhagen DJ, Gyorki DE, Hayes AJ, Kuijpers AMJ, Long GV, Mammen JMV, Menzies AM, Ross MI, Rutkowski P, Tawbi HA, Tetzlaff MT, Zager JS, Wargo JA, Hieken TJ, van Akkooi ACJ. International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma. Ann Surg Oncol, 2025. e-Pub 2025. PMID: 41087785.
6. Long GV, Nair N, Marbach D, Scolyer RA, Wilson S, Cotting D, Staedler N, Amaria RN, Ascierto PA, Tarhini AA, Robert C, Hamid O, Gaudy-Marqueste C, Lebbe C, Munoz-Couselo E, Menzies AM, Pages C, Curigliano G, Mandala M, Jessop N, Bader U, Perdicchio M, Teichgraber V, Muecke M, Markert C, Blank C. Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial. Nat Med 31(11):3700-3712, 2025. e-Pub 2025. PMID: 40993242.
7. Nelson BE, Janku F, Fu S, Dumbrava EE, Hong DS, Karp DD, Naing A, Rodon J, Tsimberidou AM, Murthy R, Sheth RA, Amaria RN, Conley AP, Damodaran S, Raghav KPS, Carapanceanu N, Singh MP, Carapanceanu V, Pezeshki A, Leontovich AA, Kreider BL, Tung D, Varterasian M, Khazaie K, Piha-Paul SA. Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Clin Cancer Res 31(18):3864-3875, 2025. e-Pub 2025. PMID: 40643985.
8. Burton EM, Milton DR, Tetzlaff MT, Wani K, Ross MI, Postow MA, Lazcano R, Glitza IC, Wong MK, Patel SP, Diab A, Gershenwald JE, McQuade JL, Betof Warner A, Prieto VG, Lee JE, Goepfert RP, Fisher SB, Song A, Malke J, Simon JM, Ariyan C, Torres-Cabala CA, Davies MA, Lazar A, Wargo JA, Tawbi HA, Amaria RN. Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma. J Clin Oncol 43(26):2856-2862, 2025. e-Pub 2025. PMID: 40638872.
9. Salem AF, Chen MM, Williams MD, Swanson DM, McQuade JL, Amaria RN, Hanna EY, Bishop AJ, Farooqi AS, Guadagnolo BA, Su SY, Mitra D. Resectable Sinonasal Mucosal Melanoma in the Immunotherapy Era: Upfront Surgery vs. Neoadjuvant Therapy. Head Neck 47(7):1848-1856, 2025. e-Pub 2025. PMID: 39906003.
10. Zhou L, Barros E Silva MJ, Hsiao E, Eroglu Z, Sandhu S, Samoylenko I, Lo SN, Carlino MS, Au-Yeung G, Gonzalez M, Spillane AJ, Pennington TE, Shannon KF, Kapoor R, Burton EM, Tawbi HA, Amaria RN, Blank CU, Duprat JP, Brito de Paula R, Gyorki DE, Saw RPM, Ch'Ng S, Rawson RV, Scolyer RA, Pires da Silva I, Akkooi ACJV, Long GV, Menzies AM. FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma. J Immunother Cancer 13(3), 2025. e-Pub 2025. PMID: 40132907.
11. Keatts SA, Salem AF, Swanson DM, Farooqi AS, Bishop AJ, Amaria RN, McQuade JL, Glitza Oliva IC, Diab A, Weiser R, Fisher SB, Goepfert RP, Ross MI, Ashleigh Guadagnolo B, Mitra D. Durable local control with hypofractionated radiation therapy for unresectable or metastatic melanoma. Clin Transl Radiat Oncol 49:100856, 2024. e-Pub 2024. PMID: 39308633.
12. Saberian, C, Milton, D, Simon, JM, Amaria, RN, Diab, A, McQuade, JL, Patel, SP, Tawbi, H, Yee, C, Wong, MK, McCutcheon, IE, Davies, MA, Ferguson, SD, Glitza, IC. Survival and treatment outcomes in patients with leptomeningeal disease from metastatic melanoma. Neuro-Oncology Practice 11(4):452-463, 2024. e-Pub 2024. PMID: 39006528.
13. Gopalakrishnan, M, Amaria, RN. Project Optimus Elicits the "Holistic" Benefits of PK/PD Modeling of Immunotherapy. Clinical Cancer Research 30(14):2862-2864, 2024. e-Pub 2024. PMID: 38743418.
14. Warner, AB, Hamid, O, Komanduri, KV, Amaria, RN, Butler, M, Haanen, JB, Nikiforow, S, Puzanov, I, Sarnaik, AA, Bishop, MR, Schoenfeld, AJ. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. Journal for immunotherapy of cancer 12(2), 2024. e-Pub 2024. PMID: 38423748.
15. Amaria, RN, Knisely, A, Vining, D, Kopetz, S, Overman, MJ, Javle, M, Antonoff, MB, Tzeng, CD, Wolff, RA, Pant, S, Lito, K, Rangel, KM, Fellman, B, Yuan, Y, Lu, KH, Sakellariou-Thompson, D, Haymaker, CL, Forget, MA, Hwu, P, Bernatchez, C, Jazaeri, AA. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. Journal for immunotherapy of cancer 12(2), 2024. e-Pub 2024. PMID: 38309721.
16. Wang, Y, Varatharajalu, K, Shatila, M, Junek, K, Ninoska, NN, Msaouel, P, Campbell, M, Amaria, RN, Thomas, AS. Randomized clinical trial of infliximab versus vedolizumab for immune checkpoint inhibitor related colitis. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
17. Marques-Piubelli ML, Seervai RNH, Mudaliar KM, Ma W, Milton DR, Wang J, Muhlbauer A, Parra ER, Solis LM, Nagarajan P, Speiser J, Hudgens C, Cho WC, Aung PP, Patel A, Pacha O, Nelson KC, Tetzlaff MT, Amaria RN, Torres-Cabala CA, Prieto VG, Wistuba II, Curry JL. Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of TH 1 T-cells. J Cutan Pathol 50(7):661-673, 2023. e-Pub 2023. PMID: 37150813.
18. Garbe C, Dummer R, Amaral T, Amaria RN, Ascierto PA, Burton EM, Dreno B, Eggermont AMM, Hauschild A, Hoeller C, Kaufmann R, Lebbe C, Mandala M, Menzies AM, Moreno D, Michielin O, Nathan P, Patel SP, Robert C, Schadendorf D, Lorigan PC, Scolyer RA, Tawbi HA, van de Wiel BA, Blank C, Long GV. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nat Med 29(6):1310-1312, 2023. e-Pub 2023. PMID: 37193799.
19. Glitza Oliva IC, Ferguson SD, Bassett R, Foster AP, John I, Hennegan TD, Rohlfs M, Richard J, Iqbal M, Dett T, Lacey C, Jackson N, Rodgers T, Phillips S, Duncan S, Haydu L, Lin R, Amaria RN, Wong MK, Diab A, Yee C, Patel SP, McQuade JL, Fischer GM, McCutcheon IE, O'Brien BJ, Tummala S, Debnam M, Guha-Thakurta N, Wargo JA, Burton EM, Tawbi HA, Davies MA. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease. Nat Med 29(4):898-905, 2023. e-Pub 2023. PMID: 36997799.
20. Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 615(7953):E23, 2023. e-Pub 2023. PMID: 36894629.
21. Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature 613(7945):E3, 2023. e-Pub 2023. PMID: 36627494.
22. Mitra D, Farr M, Nagarajan P, Ho J, Bishop AJ, Jhingran A, Farooqi AS, Frumovitz M, Amaria RN, McQuade JL, Jazaeri AA, Guadagnolo BA. Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression. Gynecol Oncol 167(3):483-489, 2022. e-Pub 2022. PMID: 36229264.
23. Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Neoadjuvant Relatlimab and Nivolumab in Resectable Melanoma. Nature 611(7934):155-160, 2022. e-Pub 2022. PMID: 36289334.
24. Mitra D, Rao PK, Nagarajan P, Bishop AJ, Farooqi AS, Gershenwald JE, Wargo J, Keung EZ, Fisher SB, Amaria RN, Davies MA, Ross MI, Guadagnolo BA. Outcomes after sphincter-sparing local therapy for anorectal melanoma: 1989-2020. Pract Radiat Oncol 12(5):437-445, 2022. e-Pub 2022. PMID: 35278716.
25. Schuler M, Zimmer L, Kim KB, Sosman JA, Ascierto PA, Postow MA, FYFL DV, van Herpen CML, Carlino MS, Johnson DB, Berking C, Reddy MB, Harney AS, Berlin JD, Amaria RN. Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-Mutant Melanoma. Clin Cancer Res 28(14):3002-3010, 2022. e-Pub 2022. PMID: 35294522.
26. Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature 606(7915):797-803, 2022. e-Pub 2022. PMID: 35705814.
27. Burton EM, Amaria RN, Cascone T, Chalabi M, Gross ND, Mittendorf EA, Scolyer RA, Sharma P, Ascierto PA. Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021. J Transl Med 20(1):271, 2022. e-Pub 2022. PMID: 35706041.
28. Creasy CA, Meng YJ, Forget MA, Karpinets T, Tomczak K, Stewart C, Torres-Cabala CA, Pilon-Thomas S, Sarnaik AA, Mulé JJ, Garraway L, Bustos M, Zhang J, Patel SP, Diab A, Glitza IC, Yee C, Tawbi H, Wong MK, McQuade J, Hoon DSB, Davies MA, Hwu P, Amaria RN, Haymaker C, Beroukhim R, Bernatchez C. Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. Clin Cancer Res 28(9):1911-1924, 2022. e-Pub 2022. PMID: 35190823.
29. Menzies AM, Pires da Silva I, Trojaniello C, Vieu E, Amaria RN, Zimmer L, Lo SN, Burton EM, Tawbi HA, Schadendorf D, Grob JJ, Ascierto PA, Long GV. CTLA-4 Blockade Resistance after Relatlimab and Nivolumab. N Engl J Med 386(17):1668-1669, 2022. e-Pub 2022. PMID: 35476655.
30. Patel AB, Farooq S, Welborn M, Amaria RN, Chon SY, Diab A, Glitza Oliva IC, Huen AO, Li SQ, Nelson KC, Pacha O, Patel SP, Rapini RP, Tawbi HA, Wong MK, McQuade J, Davies MA, Haydu LE. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. Cancer 128(5):975-983, 2022. e-Pub 2022. PMID: 34724197.
31. Ho J, Mattei J, Tetzlaff M, Williams MD, Davies MA, Diab A, Oliva ICG, McQuade J, Patel SP, Tawbi H, Wong MK, Fisher SB, Hanna E, Keung EZ, Ross M, Weiser R, Su SY, Frumovitz M, Meyer LA, Jazaeri A, Pettaway CA, Guadagnolo BA, Bishop AJ, Mitra D, Farooqi A, Bassett R, Faria S, Nagarajan P, Amaria RN. Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma. Front Oncol 12:1001150, 2022. e-Pub 2022. PMID: 36324592.
32. Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG, Peterson CB, Wong MC, Morad G, Rodgers T, Badger JH, Helmink BA, Andrews MC, Rodrigues RR, Morgun A, Kim YS, Roszik J, Hoffman KL, Zheng J, Zhou Y, Medik YB, Kahn LM, Johnson S, Hudgens CW, Wani K, Gaudreau PO, Harris AL, Jamal MA, Baruch EN, Perez-Guijarro E, Day CP, Merlino G, Pazdrak B, Lochmann BS, Szczepaniak-Sloane RA, Arora R, Anderson J, Zobniw CM, Posada E, Sirmans E, Simon J, Haydu LE, Burton EM, Wang L, Dang M, Clise-Dwyer K, Schneider S, Chapman T, Anang NAS, Duncan S, Toker J, Malke JC, Glitza IC, Amaria RN, Tawbi HA, Diab A, Wong MK, Patel SP, Woodman SE, Davies MA, Ross MI, Gershenwald JE, Lee JE, Hwu P, Jensen V, Samuels Y, Straussman R, Ajami NJ, Nelson KC, Nezi L, Petrosino JF, Futreal PA, Lazar AJ, Hu J, Jenq RR, Tetzlaff MT, Yan Y, Garrett WS, Huttenhower C, Sharma P, Watowich SS, Allison JP, Cohen L, Trinchieri G, Daniel CR, Wargo JA. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374(6575):1632-1640, 2021. e-Pub 2021. PMID: 34941392.
33. St Paul M, Saibil SD, Han S, Israni-Winger K, Lien SC, Laister RC, Sayad A, Penny S, Amaria RN, Haydu LE, Garcia-Batres CR, Kates M, Mulder DT, Robert-Tissot C, Gold MJ, Tran CW, Elford AR, Nguyen LT, Pugh TJ, Pinto DM, Wargo JA, Ohashi PS. Coenzyme A fuels T cell anti-tumor immunity. Cell Metab 33(12):2415-2427.e6, 2021. e-Pub 2021. PMID: 34879240.
34. Sloane RAS, White MG, Witt RG, Banerjee A, Davies MA, Han G, Burton E, Ajami N, Simon JM, Bernatchez C, Haydu LE, Tawbi HA, Gershenwald JE, Keung E, Ross M, McQuade J, Amaria RN, Wani K, Lazar AJ, Woodman SE, Wang L, Andrews MC, Wargo JA. Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers (Basel) 13(21), 2021. e-Pub 2021. PMID: 34771465.
35. Nebhan CA, Johnson DB, Sullivan RJ, Amaria RN, Flaherty KT, Sosman JA, Davies MA. Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study. Oncologist 26(9):731-e1498, 2021. e-Pub 2021. PMID: 33861486.
36. Corsini EM, Mitchell KG, Zhou N, Bernatchez C, Forget MA, Haymaker CL, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Amaria RN, Jazaeri AA, Antonoff MB. Pulmonary resection for tissue harvest in adoptive tumor-infiltrating lymphocyte therapy: Safety and feasibility. J Surg Oncol 124(4):699-703, 2021. e-Pub 2021. PMID: 34057733.
37. Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, Khan MAW, Cogdill AP, White MG, Wong MC, Ferrere G, Fluckiger A, Roberti MP, Opolon P, Alou MT, Yonekura S, Roh W, Spencer CN, Curbelo IF, Vence L, Reuben A, Johnson S, Arora R, Morad G, Lastrapes M, Baruch EN, Little L, Gumbs C, Cooper ZA, Prieto PA, Wani K, Lazar AJ, Tetzlaff MT, Hudgens CW, Callahan MK, Adamow M, Postow MA, Ariyan CE, Gaudreau PO, Nezi L, Raoult D, Mihalcioiu C, Elkrief A, Pezo RC, Haydu LE, Simon JM, Tawbi HA, McQuade J, Hwu P, Hwu WJ, Amaria RN, Burton EM, Woodman SE, Watowich S, Diab A, Patel SP, Glitza IC, Wong MK, Zhao L, Zhang J, Ajami NJ, Petrosino J, Jenq RR, Davies MA, Gershenwald JE, Futreal PA, Sharma P, Allison JP, Routy B, Zitvogel L, Wargo JA. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med 27(8):1432-1441, 2021. e-Pub 2021. PMID: 34239137.
38. Mitra D, Ologun G, Keung EZ, Goepfert RP, Amaria RN, Ross MI, Gershenwald JE, Lucci A, Fisher SB, Davies MA, Lee JE, Bishop AJ, Farooqi AS, Wargo J, Guadagnolo BA. Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Ann Surg Oncol 28(7):3480-3489, 2021. e-Pub 2021. PMID: 33856603.
39. Saberian C, Amaria RN, Najjar AM, Radvanyi LG, Haymaker CL, Forget MA, Bassett RL, Faria SC, Glitza IC, Alvarez E, Parshottam S, Prieto V, Lizée G, Wong MK, McQuade JL, Diab A, Yee C, Tawbi HA, Patel S, Shpall EJ, Davies MA, Hwu P, Bernatchez C. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. J Immunother Cancer 9(5), 2021. e-Pub 2021. PMID: 34021033.
40. Ogata D, Haydu LE, Glitza IC, Patel SP, Tawbi HA, McQuade JL, Diab A, Ekmekcioglu S, Wong MK, Davies MA, Amaria RN. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. Cancer Med 10(7):2293-2299, 2021. e-Pub 2021. PMID: 33686688.
41. Punt S, Malu S, McKenzie JA, Manrique SZ, Doorduijn EM, Mbofung RM, Williams L, Silverman DA, Ashkin EL, Dominguez AL, Wang Z, Chen JQ, Maiti SN, Tieu TN, Liu C, Xu C, Forget MA, Haymaker C, Khalili JS, Satani N, Muller F, Cooper LJN, Overwijk WW, Amaria RN, Bernatchez C, Heffernan TP, Peng W, Roszik J, Hwu P. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. Cancer Immunol Immunother 70(4):1101-1113, 2021. e-Pub 2021. PMID: 33123754.
42. Janku F, Sakamuri D, Kato S, Huang HJ, Call SG, Naing A, Holley VR, Patel SP, Amaria RN, Falchook GS, Piha-Paul SA, Zinner RG, Tsimberidou AM, Hong DS, Meric-Bernstam F. Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers. Cancer 127(3):391-402, 2021. e-Pub 2020. PMID: 33119140.
43. Menzies AM, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, Lo S, Tarhini AA, Burton EM, Pennington TE, Saw RPM, Xu X, Karakousis GC, Ascierto PA, Spillane AJ, van Akkooi ACJ, Davies MA, Mitchell TC, Tawbi HA, Scolyer RA, Wargo JA, Blank CU, Long GV. Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med 27(2):301-309, 2021. e-Pub 2021. PMID: 33558722.
44. Duke TC, Nair R, Torres-Cabala C, Amaria RN, Keiser E, Miranda R, Iyer SP, Heberton M. Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment. JAAD Case Rep 6(12):1264-1267, 2020. e-Pub 2020. PMID: 33294560.
45. Tetzlaff MT, Adhikari C, Lo S, Rawson RV, Amaria RN, Menzies AM, Wilmott JS, Ferguson PM, Ross MI, Spillane AJ, Vu KA, Ma J, Ning J, Haydu LE, Saw RPM, Wargo JA, Tawbi HA, Gershenwald JE, Long GV, Davies MA, Scolyer RA. Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Ann Oncol 31(11):1569-1579, 2020. e-Pub 2020. PMID: 32739408.
46. Haydu LE, Lo SN, McQuade JL, Amaria RN, Wargo J, Ross MI, Cormier JN, Lucci A, Lee JE, Ferguson SD, Saw RPM, Spillane AJ, Shannon KF, Stretch JR, Hwu P, Patel SP, Diab A, Wong MKK, Glitza Oliva IC, Tawbi H, Carlino MS, Menzies AM, Long GV, Lazar AJ, Tetzlaff MT, Scolyer RA, Gershenwald JE, Thompson JF, Davies MA. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol 38(13):JCO1901508, 2020. e-Pub 2020. PMID: 31990608.
47. Lucci A, Hall CS, Patel SP, Narendran B, Bauldry JB, Royal RE, Karhade M, Upshaw JR, Wargo JA, Glitza IC, Wong MKK, Amaria RN, Tawbi HA, Diab A, Davies MA, Gershenwald JE, Lee JE, Hwu P, Ross MI. Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clin Cancer Res 26(8):1886-1895, 2020. e-Pub 2020. PMID: 32015020.
48. Holbrook K, Lutzky J, Davies MA, Davis JM, Glitza IC, Amaria RN, Diab A, Patel SP, Amin A, Tawbi H. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. Cancer 126(3):523-530, 2020. e-Pub 2020. PMID: 31658370.
49. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautès-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577(7791):549-555, 2020. e-Pub 2020. PMID: 31942075.
50. Schvartsman G, Ma J, Bassett RL, Haydu LE, Amaria RN, Hwu P, Wong MK, Hwu WJ, Diab A, Patel SP, Davies MA, Hamerschlak N, Tawbi HA, Glitza Oliva IC. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. Cancer. e-Pub 2019. PMID: 31398264.
51. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A. Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 7(1):107, 2019. e-Pub 2019. PMID: 30995944.
52. Amaria R, Caffrey M. Finding the right combination for neoadjuvant therapy in high-risk, stage III melanoma. Am J Manag Care 25(2 Spec No):SP43-SP44, 2019. e-Pub 2019. PMID: 30776211.
53. Forget MA, Haymaker C, Amaria RN, Bernatchez C. TIL therapy and anti-CTLA4: can they co-exist?. Oncotarget 10(1):1-2, 2019. e-Pub 2019. PMID: 30713594.
54. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(12):1942, 2018. e-Pub 2018. PMID: 30361511.
55. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(12):1941, 2018. e-Pub 2018. PMID: 30361510.
56. Tavera RJ, Forget MA, Kim YU, Sakellariou-Thompson D, Creasy CA, Bhatta A, Fulbright OJ, Ramachandran R, Thorsen ST, Flores E, Wahl A, Gonzalez AM, Toth C, Wardell S, Mansaray R, Radvanyi LG, Gombos DS, Patel SP, Hwu P, Amaria RN, Bernatchez C, Haymaker C. Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma. J Immunother 41(9):399-405, 2018. e-Pub 2018. PMID: 29757889.
57. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 6(1):103, 2018. e-Pub 2018. PMID: 30305177.
58. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma. Nat Med. e-Pub 2018. PMID: 30297909.
59. McKean MA, Amaria RN. Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma. Am J Clin Dermatol 19(5):639-646, 2018. e-Pub 2018. PMID: 30039289.
60. Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clin Cancer Res 24(18):4416-4428, 2018. e-Pub 2018. PMID: 29848573.
61. Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA. Pathological assessment of Resection Specimens After Neoadjuvant Therapy for Metastatic Melanoma. Ann Oncol 29(8):1861-1868, 2018. e-Pub 2018. PMID: 29945191.
62. McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin E, Devi S, Williams L, Tieu T, Peng W, Pradeep S, Xu C, Zorro Manrique S, Liu C, Huang L, Chen Y, Forget MA, Haymaker C, Bernatchez C, Satani N, Muller F, Roszik J, Kalra A, Heffernan T, Sood A, Hu J, Amaria R, Davis RE, Hwu P. The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. J Natl Cancer Inst 110(7):777-786, 2018. e-Pub 2018. PMID: 29267866.
63. Dolkar T, Trinidad CM, Nelson KC, Amaria RN, Nagarajan P, Torres-Cabala CA, Ivan D, Prieto VG, Tetzlaff MT, Curry JL, Aung PP. Dermatologic Toxicity from Novel Therapy using Antimicrobial Peptide LL-37 in Melanoma: A Detailed Examination of the Clinicopathologic Features. J Cutan Pathol 45(7):539-544, 2018. e-Pub 2018. PMID: 29665030.
64. Farah M, Nagarajan P, Torres-Cabala CA, Curry JL, Amaria RN, Wargo J, Tawbi H, Ivan D, Prieto VG, Tetzlaff MT, Aung PP. Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall. J Cutan Pathol 45(7):545-549, 2018. e-Pub 2018. PMID: 29672900.
65. Liu L, Toung JM, Jassowicz AF, Vijayaraghavan R, Kang H, Zhang R, Kruglyak KM, Huang HJ, Hinoue T, Shen H, Salathia NS, Hong DS, Naing A, Subbiah V, Piha-Paul SA, Bibikova M, Granger G, Barnes B, Shen R, Gutekunst K, Fu S, Tsimberidou AM, Lu C, Eng C, Moulder SL, Kopetz ES, Amaria RN, Meric-Bernstam F, Laird PW, Fan JB, Janku F. Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification. Ann Oncol 29(6):1445-1453, 2018. e-Pub 2018. PMID: 29635542.
66. Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FCL, Li J, Teh JLF, Aplin AE, Chen M, Zhang J, Lazar AJ, Davies MA, Futreal PA, Amaria RN, Zhang DY, Wargo JA, Kwong LN. A pre-existing rare PIK3CAE545K subpopulation confers clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling. Cancer Discov 8(5):556-567, 2018. e-Pub 2018. PMID: 29496665.
67. Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets TV, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung R, Wang ZQ, Davis RE, Lo RS, Wargo JA, Davies MA, Bernatchez C, Heffernan TP, Amaria RN, Korkut A, Peng W, Roszik J, Lizee G, Woodman SE, Hwu P. The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. Clin Cancer Res. e-Pub 2018. PMID: 29496759.
68. Brusco LL, Wathoo C, Mills Shaw KR, Holla VR, Bailey AM, Johnson AM, Khotskaya YB, Litzenburger BC, Sanchez NS, Zeng J, Bernstam EV, Eng C, Kee BK, Amaria RN, Routbort MJ, Mills GB, Mendelsohn J, Meric-Bernstam F. Physician interpretation of genomic test results and treatment selection. Cancer 124(5):966-972, 2018. e-Pub 2018. PMID: 29165790.
69. Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, Creasy C, Leahey SE, Chen J, Chen Y, Pelicano H, Bernatchez C, Gopal YNV, Heffernan TP, Hu J, Wang J, Amaria RN, Garraway LA, Huang P, Yang P, Wistuba II, Woodman SE, Roszik J, Davis RE, Davies MA, Heymach JV, Hwu P, Peng W. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab. e-Pub 2018. PMID: 29628419.
70. Tetzlaff MT, Nelson KC, Diab A, Staerkel GA, Nagarajan P, Torres-Cabala CA, Chasen BA, Wargo JA, Prieto VG, Amaria RN, Curry JL. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer 6(1):14, 2018. e-Pub 2018. PMID: 29433571.
71. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. e-Pub 2018. PMID: 29361468.
72. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97-103, 2018. e-Pub 2018. PMID: 29097493.
73. Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MA. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open 3(1):e000283, 2018. e-Pub 2018. PMID: 29387478.
74. Glitza IC, Guha-Thakurta N, D'Souza NM, Amaria RN, McGovern SL, Rao G, Li J. Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases. Melanoma Res 27(6):580-584, 2017. e-Pub 2017. PMID: 28817446.
75. Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, Korivi BR, Landon GA, Nagarajan P, Choksi A, Chen L, Uemura M, Aung PP, Diab A, Sharma P, Davies MA, Amaria R, Prieto VG, Curry JL. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy. Report of two patients. J Cutan Pathol 44(12):1080-1086, 2017. e-Pub 2017. PMID: 28901560.
76. Mauzo SH, Tetzlaff MT, Nelson K, Amaria R, Patel S, Aung PP, Nagarajan P, Torres-Cabala CA, Diab A, Prieto VG, Curry JL. Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. Int J Dermatol. e-Pub 2017. PMID: 29152725.
77. Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C, Kuiatse I, Tieu T, Williams L, Devi S, Ashkin E, Xu C, Huang L, Zhang M, Talukder AH, Tripathi SC, Khong H, Satani N, Muller FL, Roszik J, Heffernan T, Allison JP, Lizee G, Hanash SM, Proia D, Amaria R, Davis RE, Hwu P. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nat Commun 8(1):451, 2017. e-Pub 2017. PMID: 28878208.
78. Kim DW, Haydu LE, Joon AY, Bassett RL, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA. Clinicopathological features and clinical outcomes associated with TP53 and BRAF(N)(on-)(V)(600) mutations in cutaneous melanoma patients. Cancer 123(8):1372-1381, 2017. e-Pub 2017. PMID: 27911979.
79. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 9(379), 2017. e-Pub 2017. PMID: 28251903.
80. Qin Y, Petaccia de Macedo M, Reuben A, Forget MA, Haymaker C, Bernatchez C, Spencer CN, Gopalakrishnan V, Reddy S, Cooper ZA, Fulbright OJ, Ramachandran R, Wahl A, Flores E, Thorsen ST, Tavera RJ, Conrad C, Williams MD, Tetzlaff MT, Wang WL, Gombos DS, Esmaeli B, Amaria RN, Hwu P, Wargo JA, Lazar AJ, Patel SP. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. Oncoimmunology 6(6):e1321187, 2017. e-Pub 2017. PMID: 28680759.
81. Forget MA, Tavera RJ, Haymaker C, Ramachandran R, Malu S, Zhang M, Wardell S, Fulbright OJ, Toth CL, Gonzalez AM, Thorsen ST, Flores E, Wahl A, Peng W, Amaria RN, Hwu P, Bernatchez C. A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes. Front Immunol 8:908, 2017. e-Pub 2017. PMID: 28824634.
82. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2, 2017. e-Pub 2017. PMID: 28819565.
83. McQuade JL, Posada LP, Lecagoonporn S, Cain S, Bassett RL, Patel SP, Hwu WJ, Hwu P, Davies MA, Bedikian AY, Amaria RN. A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. Melanoma Res 26(6):604-608, 2016. e-Pub 2016. PMID: 27540836.
84. Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol 2(8):1056-64, 2016. e-Pub 2016. PMID: 27124486.
85. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov 6(8):827-37, 2016. e-Pub 2016. PMID: 27301722.
86. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology 5(3):e1136044, 2016. e-Pub 2016. PMID: 27141370.
87. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 6(2):202-16, 2016. e-Pub 2016. PMID: 26645196.
88. Schmitt RJ, Kreidler SM, Glueck DH, Amaria RN, Gonzalez R, Lewis K, Bagrosky BM, Kwak JJ, Koo PJ. Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma. Nucl Med Commun 37(2):122-8, 2016. e-Pub 2016. PMID: 26440571.
89. Gerami P, Cook RW, Russell MC, Wilkinson J, Amaria RN, Gonzalez R, Lyle S, Jackson GL, Greisinger AJ, Johnson CE, Oelschlager KM, Stone JF, Maetzold DJ, Ferris LK, Wayne JD, Cooper C, Obregon R, Delman KA, Lawson D. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol 72(5):780-5.e3, 2015. e-Pub 2015. PMID: 25748297.
90. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF(V600): Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. J Invest Dermatol 135(2):508-15, 2015. e-Pub 2015. PMID: 25148578.
91. Gerami P, Cook RW, Wilkinson J, Russell MC, Dhillon N, Amaria RN, Gonzalez R, Lyle S, Johnson CE, Oelschlager KM, Jackson GL, Greisinger AJ, Maetzold D, Delman KA, Lawson DH, Stone JF. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res 21(1):175-83, 2015. e-Pub 2015. PMID: 25564571.
92. Reuben A, RNb B, Cooper ZA, Wargo JA. RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma. J Pigment Disord 1(5), 2014. e-Pub 2014. PMID: 29250602.
93. Cooper ZA, Reuben A, Amaria RN, Wargo JA. Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. Oncoimmunology 3(9):e954956, 2014. e-Pub 2014. PMID: 25941608.
94. Jordan KR, Amaria RN, Ramirez O, Callihan EB, Gao D, Borakove M, Manthey E, Borges VF, McCarter MD. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother 62(11):1711-22, 2013. e-Pub 2013. PMID: 24072401.
95. Amaria R, Schefter TE, Durham J, Pita De Oliveira LO, Kane M. Selective internal radiotherapy in metastatic esophageal adenocarcinoma. Gastrointest Cancer Res 4(5-6):191-3, 2011. e-Pub 2011. PMID: 22295134.
96. Amaria RN, Corboy JR, Finlayson CA, Robinson WA, Borges VF. Immunomodulatory therapy in multiple sclerosis and breast cancer risk: a case report and literature review. Clin Breast Cancer 8(5):449-52, 2008. e-Pub 2008. PMID: 18952560.
97. Abdel-Halim SM, Gross DJ, Clark A, Poitout V, Amaria R, Ostenson CG, Hutton JC. Proinsulin processing in the diabetic Goto-Kakizaki rat. J Endocrinol 175(3):637-47, 2002. e-Pub 2002. PMID: 12475375.

Invited Articles

1. Hieken TJ, Kreidieh F, Aedo-Lopez V, Block MS, McArthur GA, Amaria RN. Neoadjuvant Immunotherapy in Melanoma: The Paradigm Shift. Am Soc Clin Oncol Educ Book 43:e390614, 2023. e-Pub 2023. PMID: 37116111.
2. McKean M, Amaria R. Using adoptive cell therapy in the modern era of Metastatic Melanoma treatment. Clinical Skin Cancer 2(1-2):32-38, 2017. e-Pub 2017.
3. Kim T, Amaria RN, Spencer C, Reuben A, Cooper ZA, Wargo JA. Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med 11(4):237-46, 2014. e-Pub 2014. PMID: 25610709.
4. Amaria RN, Kim KB. Dabrafenib for the treatment of melanoma. Expert Opin Pharmacother 15(7):1043-50, 2014. e-Pub 2014. PMID: 24720932.
5. Medina T, Amaria RN, Jimeno A. Dabrafenib in the treatment of advanced melanoma. Drugs Today (Barc) 49(6):377-85, 2013. e-Pub 2013. PMID: 23807941.
6. Amaria RN, Bowles DW, Lewis KD, Jimeno A. Vismodegib in basal cell carcinoma. Drugs Today (Barc) 48(7):459-67, 2012. e-Pub 2012. PMID: 22844657.
7. Amaria RN, Lewis KD, Jimeno A. Vemurafenib: the road to personalized medicine in melanoma. Drugs Today (Barc) 48(2):109-18, 2012. e-Pub 2012. PMID: 22384451.
8. Scott A, Amaria R, Lewis K. Adjuvant peginterferon alfa-2b therapy in stage II melanoma. Expert Review of Dematology 6(6):567-575, 2011. e-Pub 2011.
9. Scheier B, Amaria R, Lewis K, Gonzalez R. Novel therapies in melanoma. Immunotherapy 3(12):1461-9, 2011. e-Pub 2011. PMID: 22091682.
10. Amaria RN, Lewis KD, Gonzalez R. Therapeutic options in cutaneous melanoma: latest developments. Ther Adv Med Oncol 3(5):245-51, 2011. e-Pub 2011. PMID: 21957431.

Review Articles

1. Mattei J, Ruitao L, Davies MA, Wong MK, Diab A, Haydu LE, Patel SP, Amaria RN, McQuade JL, Tawbi H, Burton EM, Glitza IC. Adjuvant therapy in mucosal melanoma: a single-center experience and review of the literature. Melanoma Res 36(1):31-42, 2026. e-Pub 2026. PMID: 41337670.
2. Amaria RN, Komanduri KV, Schoenfeld AJ, Ramsingh G, Burga RA, Jagasia MH. Entering a new era of tumor-infiltrating lymphocyte cell therapy innovation. Cytotherapy 27(7):864-873, 2025. e-Pub 2025. PMID: 40131263.
3. Buchbinder, E, Lotze, MT, Margolin, K, Amaria, RN, Sarnaik, AA, Seery, V, Eroglu, Z, Khaddour, K, Warner, AB, Kluger, H, Sznol, M, Atkins, MB, McDermott, DF, Willman, A. Role of high-dose interleukin-2 for melanoma in the age of cellular therapy. Journal for immunotherapy of cancer 13(5), 2025. e-Pub 2025. PMID: 40447314.
4. Pelster MS, Amaria RN. Neoadjuvant Immunotherapy for Locally Advanced Melanoma. Curr Treat Options Oncol 21(2):10, 2020. e-Pub 2020. PMID: 32025932.
5. Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA, Consortium members INM, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol 20(7):e378-e389, 2019. e-Pub 2019. PMID: 31267972.
6. Pelster MS, Amaria RN. Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. Ther Adv Med Oncol 11:1758835919830826, 2019. e-Pub 2019. PMID: 30815041.
7. McKean MA, Amaria RN. Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy. Cancer Treat Rev 70:144-153. e-Pub 2018. PMID: 30195813.
8. RNb B, Reuben A, Cooper ZA, Wargo JA. Update on use of aldesleukin for treatment of high-risk metastatic melanoma. Immunotargets Ther 4:79-89, 2015. e-Pub 2015. PMID: 27471714.
9. Hutton J, Wasmeier C, Amaria R, Bright N, Creemers J. Proprotein processing and pancreatic islet function. Adv Exp Med Biol 552:39-65, 2004. e-Pub 2004. PMID: 15622958.

Other Articles

1. Lucas MW, Burton EM, Dimitriadis P, Huang AC, Long GV, Mitchell TC, Amaria RN, Blank CU Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity. Immunity 59(1):29-33.e2, 2026. PMID: 41478279.
2. Glitza, IC, Ferguson, SD, Bassett Jr, R, Foster, AP, John, I, Hennegan, TD, Rohlfs, ML, Richard, J, Iqbal, M, Dett, TK, Lacey, C, Jackson, N, Rodgers, TE, Phillips, S, Duncan, S, Haydu, LE, Lin, R, Amaria, RN, Wong, MK, Diab, A, Yee, C, Patel, SP, McQuade, JL, Fischer, G, McCutcheon, IE, O'Brien, BJ, Tummala, S, Debnam, M, Guha-Thakurta, N, Wargo, J, Carapeto, F, Hudgens, CW, Huse, J, Tetzlaff, M, Burton, EM, Tawbi, H, Davies, MA Author Correction. Nature medicine 30(6):1787, 2024. PMID: 38649781.
3. Amaria RN First-Line Therapy in Advanced BRAF-Mutant. ASCO Daily News, 2017.

Abstracts

1. Amaria RN, McQuade JL, Davies MA, Glitza IC, Jose S, Kraske Cressman EN, Clausell AL, Bassett Jr RL, Patel SP, Diab A, Tawbi HA, Wong MK, Ikeguchi A, Haymaker CL, Lee S, Jagasia MH, Ramsingh G, Prabhakar P, Duan R, N Hari AP. OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma 42(16), 2024. e-Pub 2024.
2. Hennegan T, Burton EM, Simpson L, Prieto VG, Ross MI, Glitza IC, Beal LG, Gershenwald JE, Tawbi HA, Wong MK, Wang Z, Bassett RL, Lucci A, Lee JE, Fisher SB, Patel SP, McQuade JL, Davies MA, Wargo JA, Amaria RN. Expanded cohort and extended follow-up of neoadjuvant plus adjuvant (neo + adj) dabrafenib (D) and trametinib (T) in patients (pts) with surgically resectable stage (stg) III/IV melanoma. ASCO 2023 41(16), 2023. e-Pub 2023.
3. Amaria RN, Ma P, Tetzlaff MT, Ross MI, Glitza IC, McQuade JL, Wong MKK, Gershenwald JE, Goepfert R, Keung EZY, Fisher SB, Milton DR, Patel SP, Diab A, Simpson L, Davies MA, Wargo JA, Burton EM, Ariyan CE, Tawbi HAH. Neoadjuvant and adjuvant nivolumab with anti-LAG3 antibody relatlimab for patients with resectable clinical stage III melanoma ASC 39(15), 2021. e-Pub 2021.
4. Amaria RN, Haymaker C, Forget MA, Bassett R, Cormier JN, Davies MA, Diab A, Gershenwald JE, Glitza IC, Lee JE, Lucci A, McQuade JM, Patel SP, Royal R, Ross MI, Tawbi HA, Wargo JA, Wong MK, Bernatchez C, Hwu P. Lymphodepletion (LD), tumor-infiltrating lymphocytes (TIL) and high (HD-IL2) versus low dose (LD-IL2) IL-2 followed by pembrolizumab (pembro) in patients (pts) with metastatic melanoma (MM), 2019. e-Pub 2019.
5. Menzies AM, Rozeman EA, Amaria RN, Huang AC, Scolyer RA, Tetzlaff M, van de Wiel BA, Lo S, Tarhini A, Tawbi H, Burton EM, Karakousis GC, Ascierto P, Spillane A, Davies MA, van Akkooi ACJ, Mitchell T, Long GV, Wargo JA, Blank CU. Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC), 2019. e-Pub 2019.
6. Amaria RN, Reddy S, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Burton EM, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in patients with high-risk resectable metastatic melanoma, 2018. e-Pub 2018.
7. Amaria RN, Haymaker C, Forget MA, Patel V, Carpio D, Patel SP, Hwu WJ, Wong W, Davies M, Diab A, Glitza IC, Tawbi H, Bernatchez C, Hwu P. TFG-β Dominant Negative Receptor (TGF-DNRII) and NGFR-trnasduced tumor infiltrating lymphocytes and high dose interleukin-2 in patients with metastatic melanoma, 2017. e-Pub 2017.
8. Diab A, Haymaker C, Uemura M, Murthy R, James M, Geib J, COrnfeld M, Swann S, Yee C, Wargo J, Amaria RN, Patel S, Tawbi H, GLitza I, Woodman S, Hwu WJ, Davies M, Overwijk W, Bernatchez C, Hwu P. A Phase 1/2 trial of Intratumoral (i.t.) IMO-2125 (IMO) in combinaiton with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma. ESMO 2017. e-Pub 2017.
9. Jassowicz A, Liu I, Huang H, Hong DS, Naing A, Subbiah V, PIha-Paul SA, TOung J, Vijayaraghavan R, Zhang R, Kang H, Fu S, Tsimberidou AM, Lu C, Eng C, Moulder S, Kopetz S, Amaria RN, Meric-Bernstam F, Janku F. Targeted methylation sequencing of plasma cell-free DNA identifies patients with advanced breast, colorectal, non-small cell lung cancer, melanoma with poor outcomes. e-Pub 2017.
10. Royal R, Vence L, Wray T, Cormier J, Lee J, Gershenwald J, Ross M, Wargo J, Amaria RN, Davies M, Diab A, Glitza I, Hwu WJ, Patel S, Woodman S, Overwijk W, Hwu P. A toll-like receptor agonist to drive melanoma regression as a vaccination adjuvant ot by direct tumor application, 2017. e-Pub 2017.
11. Schvartsman G, Ma J, Bassett R, Haydu L, Amaria RN, Hwu P, Hwu WJ, Diab A, Patel S, Davies M, Tawbi H, Glitza I. Incidence, patterns of progression and outcomes of melanoma brain metastasis (MBM) during programmed-death 1 inhibitor (PD1i) therapy, 2017. e-Pub 2017.
12. Menzies A, Rozeman E, Amaria RN, Scolyer R, Tetzlaff M, Guminski A, Davies M, Blank C, Wargo J, Long G. Preliminary results from the international neoadjuvant melanoma consortium (INMC), 2017. e-Pub 2017.
13. McKean M, Haydu L, Ma J, Bassett R, Hwu WJ, Patel S, Diab A, Glitza I, Tawbi H, Wong M, McQuade J, Hwu P, Davies M, Amaria RN. Prognostic factors for overall survival (OS) in metastatic melanoma (MM) patients (pts) treated with immune checkpoint inhibitors: A single institution study of 696 pts. e-Pub 2017.
14. Chen W, Andrews M, Spencer C, Tawbi H, Lazar A, Tetzlaff M, Patel S, Hwu P, Hwu WJ, Diab A, Glitza I, Amaria RN, Burton E, Woodman S, Davies M, Gershenwald J, Sharma P, Allison J, Futreal A, Wargo J. Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melanoma (MM) patients (pts), 2017. e-Pub 2017.
15. Patel S, Glitza I, Diab A, Amaria RN, Davies M, Hwu P, Tawbi H, Hwu WJ. The safety and early efficacy of high-dose ipilimumab (IPI) and the combination nivolumab plus ipilimumab (NIVO + IPI) in patients (pts) with uveal melanoma (UM). e-Pub 2017.
16. Wargo J, Amaria RN, Prieto P, Andrews M, Tetzlaff M, FUtreal A, Hwu P, Hwu WJ, Glitza I, Tawbi H, Cormier J, Lee J, Patel S, Simpson L, Burton E, Bassett R, Ross M, Gershenwald J, Davies M, Woodman S. Relapse-free survival and target identification to enhance responce with noeadjuvant and adjuvant dabrafenib + trametinib (D+T) treatment compared to standard-of-care (SOC) surgery in patients (pts) with high-risk resectable BRAF-mutant metastatic melanoma, 2017. e-Pub 2017.
17. Schuler M, Ascierto P, Leon De Vos F, Postow M, Herpen C, Carlino M, Sosman J, Berking C, Long G, Weise A, Gutzmer R, Kaatz M, McArthur G, Schwartz G, Daud A, Maharry K, Yerramilli-Rao P, Zimmer L, Bozon V, Amaria RN. Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D). e-Pub 2017.
18. Keung E, Burton E, Amaria RN, Glitza I, Patel S, Diab A, Yee C, Wong M, Hwu WJ, Hwu P, Woodman S, Tetzlaff M, Milton D, Perez K, Davies M, Rai K, Wargo J, Tawbi H. A phase II of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in paitents with metastatic melanoma (MM). ASCO 2017. e-Pub 2017.
19. Uemura M, Haymaker C, Murthy R, James M, Cornfeld M, Chunduru S, Agrawal S, Yee C, Wargo J, Amaria RN, Patel S, Tawbi H, Glitza I, Woodman S, Hwu WJ, Davies M, Hwu P, Overwijk W, Bernatchez C, Diab A. Intratumoral (i.t.) IMO-2125 (IMO), a TLR9 agonist, in combination with ipilimumab (ipi) in PD-(L)1 refractory melanoma (RM). e-Pub 2017.
20. Forget M, Haymaker C, Hess K, Roszik J, Woodman S, Fulbright O, Wahl A, FLores E, Thorsen S, Tavera R, Ramachandran R, Amaria RN, Hwu P, Bernatchez C. The impact of checkpoint blockade prior to adoptive cell therapy using tumor-infiltrating lymphocytes for metastatic melanoma: An update from MD Anderson Cancer Center. e-Pub 2017.
21. Amaria RN, Prieto PA, Tetzlaff MT, Diab A, Patel SP, Woodman SE, Hwu WJ, Glitza IC, Hwu P, Tawbi H, McQuade J, Cormier J, Lucci A, Royal R, Lee JE, Bassett R, Simpson L, Burton E, Grimm E, Reuben A, Spencer C, Gershenwald J, Davies MA, Ross M, Wargo JA. Treatment with Neoadjvant and Adjuvant Dabrafenib and Trametinib (D+T) is Associated with Improved Relapse-Free Survival (RFS) versus Standard of Care (SOC) Therapy in Patients with High-Risk Resectable BRAF-Mutant Melanoma. Presented at Society of Melanoma Research, Boston, MA, 2016. e-Pub 2016.
22. Barcena E, Trinh V, McIntyre S, Simien R, Cain S, Diab A, Amaria RN, Patel S, Glitza I, Tawbi H, Davies M, Hwu WJ. Responses in patients with BRAF V600-mutant metastatic melanoma receiving anti-PD1/PDL1 therapy alone or combined with BRAF inhibitors. e-Pub 2016.
23. Rohlfs M, Bassett R, Lacey C, McQuail N, Mehta U, John I, Simien R, Tupue S, Dett T, Glitza I, Diab A, Amaria RN, Tawbi H, Davies M, Hwu WJ, Hwu P, Patel S. BRAF with or without MEK inhibition plus PD-1 checkpoint blockade for the treatment of metastatic melanoma, 2016. e-Pub 2016.
24. Shaw A, Trinh V, Bassett R, Glitza I, Diab A, Amaria RN, Tawbi H, Davies M, Hwu WJ, Hwu P, Patel S. Retrospective analysis of safety and efficacy of ipilimumab in elderly patients with advanced melanoma. e-Pub 2016.
25. Mian I, Yang M, Zhao H, Shah M, Diab A, Shannon V, Patel A, Amaria RN, Giordano S, Suarez-Almazor M. Immune-related adverse events and survival in elderly patients with melanoma treated with ipilimumab. e-Pub 2016.
26. Amaria RN, Haymaker C, Bernatchez C, FOrget M, Patel V, Hwu WJ, Davies M, Patel S, Diab A, Glitza I, Tawbi H, Woodman S, Wargo J, Ross M, Lee J, Gershenwald J, Cormier J, Royal R, Lucci A, Hwu P. A phase I/II study of lymphodepletion plus adoptive cell transfer (ACT) with T cells tranduced with CXCR2 and NGFR followed by high dose interlukin-2 (IL-2) in patients with metastatic melanoma (MM). ASCO 2016. e-Pub 2016.
27. Amaria RN, Haymaker CK, Bernatchez C, Forget AM, Patel V, Hwu WJ, Davies MA, Patel SP, Diab A, Glitza IC, Tawbi HA, Woodman SE, Wargo JA, Ross MI, Lee JE, Gershenwald JE, Cormier JA, Royal RE, Lucci A, Hwu P. A phase I/II study of lymphodepletion plus adoptive cell transfer (ACT) with T cells transduced with CXCR2 and NGFR followed by high dose interleukin-2 (IL-2) in patients with metastatic melanoma (MM), 2016. e-Pub 2016.
28. Reuben A, Spencer C, Prieto P, Miller J, Mao X, Chen W, Cheung H, Jiang H, Haymaker C, Petaccia De Macedo M, Garber H, Chen P, Gopalakrishnan V, Austin Breneman J, Hudgens C, Roszik J, Hwu P, Woodman S, Chin L, Davies M, Amaria R, Patel S, Lazar A, Tetzlaff M, Dwyer K, Wistuba I, Sharma P, Allison J, Zhiang J, Futreal A, Cooper Z, Wargo J. Genomic and immune heterogeneity in synchronous melanoma metastases is associated with differential tumor growth and response to therapy, 2016. e-Pub 2016.
29. Reuben A, Spencer C, Roszik J, Miller J, Kwong L, Jiang H, Haymaker C, Chen P, Austin-Breneman J, Roh W, Little L, Cao Y, Garber H, Forget M, Gopalakrishnan V, Amaria RN, Davies M, Bernatchez C, Roger E, Cuentas P, Rodriguez J, Tetzlaff M, Woodman S, Dwyer K, Sharma P, Allison J, Chin L, Futreal A, Cooper Z, Wargo J. Molecular and immune heterogeneity in synchronous melanoma metastases 3, 2015. e-Pub 2015.
30. Kim DW, Haymaker C, McQuail N, Sirmans E, Spencer C, Glitza I, Amaria RN, Woodman S, Patel S, Davies M, Yee C, Hwu WJ, Bernatchez C, Wargo J, Sharma P, Allison J, Hwu P, Tam A, Diab A. Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint bloackade in patients with metastatic melanoma (MM) 3, 2015. e-Pub 2015.
31. Wargo J, Amaria RN, Ross M, Robyn S, Gershenwald J, Hwu P, Patel S, Glitza I, DIab A, Kefford R, Scolyer R, Rizos H, THompson J, Shannon K, Spillane A, Carlino M, Guminski A, Simpson L, Davies M, Long G. Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage II and IV melanoma. e-Pub 2015.
32. Amaria RN, Bassett RL, Simspon L, Delaney F, Hwu P, Kim K, Hwu WJ, Patel SP, Glitza IC, Davies MA, Woodman SE, Yee C, Bedikian AY. Phase I study of ipilimumab (IPI) with biochemotherapy (BCT) for chemonaive patients with metastatic melanoma (MM) 33, 2015. e-Pub 2015.
33. McQuade JL, Chen G, Panka DJ, Reuben A, Bassett RL, Joon A, Lazar AJF, Tetzlaff MT, Simspon L, Mouton R, Patel SP, Glitza IC, Hwu WJ, Amaria RN, Diab A, Hwu P, Wargo JA, Sullivan RJ, Kim K, Davies MA. Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastaticmelanoma: Exploration of clinical and molecular predictors of response 33, 2015. e-Pub 2015.
34. Perdon KM, Kim DW, Balmes GC, Trinh VA, McIntyre SE, Diab A, Amaria RN, Patel SP, Hwu P, James M, Phillip A, Vardeleon A, Cain S, Hwu WJ. A single-institution experience with the pembrolizumab (PEM) expanded access program (EAP). ASCO 2015 33, 2015. e-Pub 2015.
35. Lawson DH, Cook RW, Johnson C, Russell MC, Amaria RA, Wilkinson J, Gerami P, Maetzold D, Ferris L, Oelschlager KM, Greisinger A, Gonzalez R, Windham TC, Middlebrook B, Delman KA, Lyle S. Continued evaluation of a 31-gene expression profile test (GEP) for prediction of distant metastasis (DM) in cutaneous melanoma (CM). ASCO 2015 33, 2015. e-Pub 2015.
36. Amaria RN, Wargo JA, Cooper ZA, Tetzlaff MT, Reuben A, Davies MA, Gershenwald JE, Jian H, Breneman JA, Lee JE, Hwu P, Hwu WJ, Cormier JN, Royal RE, Lucci A, Patel SP, Diab A, Glitza IC, Burton EM, Ross MI. Treatment with neoadjuvant BRAF inhibition yields responses in patients (pts) with high risk borderline resectable stage III melanoma 33, 2015. e-Pub 2015.
37. Reuben A, Cooper Z, Amaria RN, Forget M, Haymaker C, Bernatchez C, Chen P, Tetzlaff M, Chin L, Dwyer K, Wargo J. Intra-patient intra-tumoral immune heterogeneity is evident at progression on targeted therapy and immunotherapy for melanoma 2. e-Pub 2014.
38. Amaria RN, Hwu WJ, Patel SP, Kim K, Papadopoulos NE, Hwu P, Bedikian AY. Phase I/II study of weekly LOC-paclitaxel (LOC-pac) injection in patients (pts) with metastatic melanoma (MM) 32(5s), 2014. e-Pub 2014.
39. Glitza IC, Bernatchez C, Bassett RL, Vaughn C, Velasquez P, Diab A, Amaria RN, Yee C, Woodman SE, Patel SP, Kim K, Davies MA, Papadopoulos NE, Bedikian AY, Hwu WJ, Radvanyi LG, Hwu P. Treatment with tumor-infiltrating lymphocytes (TIL) in metastatic melanoma and clinical benefit regardless of site of origin, mutation status, or prior checkpoint blockade 32(5s), 2014. e-Pub 2014.
40. Lawson DH, Russell MC, Wilkinson J, Jackson GL, Greisinger A, Amaria RN, Gonzalez R, Lyle S, Johnson C, Oelschlager KM, Stone JF, Maetzold D, Cook RW, Ferris L, Delman KA, Gerami P. Gene expression profile test (GEP) prediction of metastasis-free (MFS) and overall survival (OS) in a cohort of cutaneous melanoma (CM) patients undergoing sentinel lymph node biopsy (SLNB) 32(5s), 2014. e-Pub 2014.
41. Lawson D, Russell M, Wilkinson J, Amaria RN, Gonzalez R, Gerami P, Lyle S, Jackson G, Greisinger A, Robbins J, Johnson C, Oelschlager K, Maetzold D, Cook R, Delman K. Gene expression profie of primary cutaneous melanomas accurately distinguishes between low and high risk of metastasis. Journal of Clinical Oncology 31(15 suppl), 2013. e-Pub 2013.
42. Jordan KR, Amaria RN, Callihan E, Borges VF, McCarter MD. Immunosuppression in human melanoma, 2012. e-Pub 2012.
43. Diamond JR, Amaria R, O'Donnell CI, Meltesen L, Swisshelm K, Malancon D, McGavran L, Singh M, Elias A, Borges VF. The incidence of low-level HER2 gene amplification and chromosome 17 polysomy in cases of newly diagnosed breast cancer and their association with clinical prognostic markers 27 (suppl), 2009. e-Pub 2009.
44. Amaria RN. A Phase 1/2 Study of KSQ-001EX: An autologous Tumor-Infiltrating Lymphocyte Therapy engineered to inactivate the SOCS1 gene in Patients with Select Advanced Solid Tumors. SITC 2024.
45. Amaria RN. A phase 2/3 peri-operative study of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus anti–PD-1 alone in patients with resectable stage III and IV melanoma. SMR 2024.

Book Chapters

1. Bowman, S, Amaria, RN, Lu, H. Inflammatory Arthritis Post Immune Checkpoint Inhibitor Therapy, 417-423, 2025.
2. Faria, SC, Amaria, RN, Patnana, M. Melanoma, 630-655, 2022.
3. Amaria RN, Gonzalez R. Updated approach to the patient with metastatic melanoma. In: Emerging cancer therapeutics. Demos Publishing, 583-602, 2012.